Defining typical appearance as a goal of health service provision is harmful and unnecessary for traits that are stigmatized but neither harmful nor distressing.
AMA J Ethics. 2021;23(7):E569-575. doi:
10.1001/amajethics.2021.569.
Bjorg Thorsteinsdottir, MD, Annika Beck, and Jon C. Tilburt, MD, MPH
Good clinicians understand why a patient is asking for a test or treatment, and their skillful counseling can often stem the tide of requests for marginally beneficial tests and procedures.
AMA J Ethics. 2015;17(11):1028-1034. doi:
10.1001/journalofethics.2015.17.11.ecas2-1511.
Financial relationships are common, and ethical questions rightly emerge about how conflicts of interest compromise investigators’ approaches to research.
AMA J Ethics. 2021;23(9):E685-691. doi:
10.1001/amajethics.2021.685.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Editorial fellow Dr Ariel Wampler describes what few know about material and device regulation, and Dr Adriane Fugh-Berman explains why we should ask more questions about device representatives’ intraoperative roles during implantations.
Jeffrey Bedard joins Ethics Talk to discuss his article: "What Should Patients Be Told About Device Representatives’ Roles at the Point of Surgical Care?"
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"